Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1

Conditions

Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Multiple Myeloma 1Mesothelioma, Malignant 1Lymphoma, Large B-Cell, Diffuse 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Lobular 1

Interventions

Cisplatin 28Pemetrexed 22Gemcitabine 10Nivolumab 9Carboplatin 9pembrolizumab 8tremelimumab 5durvalumab 5atezolizumab 5Radiotherapy 5Doxorubicin 4Chemotherapy, Adjuvant 4Vinorelbine 3Ipilimumab 3Bortezomib 3Bevacizumab 3tumor necrosis factor-alpha, CNGRC fusion protein, human 2sodium thiosulfate 2sargramostim 2niraparib 2nintedanib 2liposomal doxorubicin 2lenvatinib 2defactinib 2cemiplimab 2cediranib 2amatuximab 2Trabectedin 2Neoadjuvant Therapy 2Mitomycin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Mesothelioma, Malignant × Drugs, Generic × Clear all
NCT04914897 2025-10-02

A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma (Pegathor Lung 202)

Sanofi

Phase 2 Terminated
106 enrolled 21 charts
Other solid neoplasmThoracic

Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡